OTSU Stock Overview
Manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Otsuka Pakistan Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨129.39 |
| 52 Week High | PK₨185.89 |
| 52 Week Low | PK₨71.10 |
| Beta | 0.39 |
| 1 Month Change | -4.18% |
| 3 Month Change | 0.015% |
| 1 Year Change | 77.20% |
| 3 Year Change | -56.21% |
| 5 Year Change | -4.83% |
| Change since IPO | 673.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| OTSU | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | -1.7% | 1.7% | 2.6% |
| 1Y | 77.2% | 64.1% | 59.5% |
Return vs Industry: OTSU exceeded the PK Pharmaceuticals industry which returned 64.1% over the past year.
Return vs Market: OTSU exceeded the PK Market which returned 59.5% over the past year.
Price Volatility
| OTSU volatility | |
|---|---|
| OTSU Average Weekly Movement | 6.2% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PK Market | 7.8% |
| 10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: OTSU has not had significant price volatility in the past 3 months.
Volatility Over Time: OTSU's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 362 | Moin-ur Rehman | www.otsuka.pk |
Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company’s products include electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products, such as aminoleban oral, proten gold, pan-amin G, aminoleban injection, and aminovel 600; and therapeutic drugs, which include mucosta tablets and pletaal, as well as oral rehydration therapy. It also engages in the trading of pharmaceutical products, nutritional foods, and medical equipment.
Otsuka Pakistan Limited Fundamentals Summary
| OTSU fundamental statistics | |
|---|---|
| Market cap | PK₨1.57b |
| Earnings (TTM) | PK₨37.02m |
| Revenue (TTM) | PK₨3.01b |
42.3x
P/E Ratio0.5x
P/S RatioIs OTSU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTSU income statement (TTM) | |
|---|---|
| Revenue | PK₨3.01b |
| Cost of Revenue | PK₨2.39b |
| Gross Profit | PK₨626.73m |
| Other Expenses | PK₨589.71m |
| Earnings | PK₨37.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.06 |
| Gross Margin | 20.80% |
| Net Profit Margin | 1.23% |
| Debt/Equity Ratio | 152.7% |
How did OTSU perform over the long term?
See historical performance and comparison